Market Size of Global Auto-Injectors Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 10.84 Billion |
Market Size (2029) | USD 22.83 Billion |
CAGR (2024 - 2029) | 16.05 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Auto-injectors Market Analysis
The Global Auto-Injectors Market size is estimated at USD 10.84 billion in 2024, and is expected to reach USD 22.83 billion by 2029, growing at a CAGR of 16.05% during the forecast period (2024-2029).
The COVID-19 pandemic has exerted favorable and unfavorable impacts on the healthcare industry. This is likely because most autoinjector products are administered at home by the patient. Patients who use autoinjectors don't have to leave their homes to receive care, which is advantageous when trying to maintain social distance during the pandemic. The rising COVID-19 patient population is putting a strain on hospital systems and the availability of medical supplies for each patient and the hospital. Due to increased demand for medical supplies such as injections, pre-filled syringes, and other items, manufacturers have increased their production capacity to meet the demand-supply balance. Covid-19 has had a significant impact on the market for auto-injectors.
The factors that are driving the market growth include increasing demand for the convenience of patients, rising incidence of chronic and lifestyle diseases, and technological advancements. According to World Health Organization Reports, in 2021, over 16 billion injections were given annually worldwide. Thus, the rising number of injections annually drives the demand for auto-injectors, thereby boosting the market.
According to the World Health Organization (WHO), the prevalence of chronic diseases is expected to rise by 57% by 2020, and 60% of this burden is likely to occur in emerging markets. Chronic diseases (CD) of various types are found to be the leading causes of disability and morbidity around the world. According to the Globocan 2020 report, 19,292,789 new cancer cases were diagnosed worldwide, with 9,958,133 cancer-related deaths. Furthermore, according to the International Diabetes Federation Report in December 2021, Diabetes affects approximately 537 million adults aged 20 to 79. By 2030, the total number of diabetics is expected to reach 643 million; by 2045, it will reach 783 million. Three out of every four adults with diabetes live in a low- or middle-income country. Moreover, according to the World Health Organization 2020 report, in 2020, it was estimated that around 10 million people suffered from tuberculosis globally. This includes 5.6 million men, 3.3 million women, and 1.1 million children. Tuberculosis affects people of all ages and from all countries. The 30 most affected countries by tuberculosis accounted for 86% of new cases in 2020. India leads the pack with two-thirds of the total, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Thus, the increase in the number of chronic diseases boosts the market growth over the forecast period.
The use of an auto-injector has brought many benefits for both the patient and healthcare professional. It has simplified self-administration, reduced anxiety, improved safety, and improved compliance. Furthermore, with the tremendous opportunity in the market, many market players are adopting various strategies, such as collaborations, acquisitions, new product launches, and expansions. For instance, in September 2021, Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd, launched its new Aidaptus auto-injector platform following the successful completion of development. Additionally, in July 2021, Otsuka Pharmaceutical Co., Ltd. (Otsuka) applied to Japan's Ministry of Health, Labour, and Welfare for an additional dosage form, auto-injector, for AJOVY Subcutaneous Injection 225 mg (a generic name is fremanezumab).
Thus, the abovementioned factors are expected to drive market growth over the forecast period. However, preference for alternative dosage delivery modes and regulatory hurdles may hinder the growth of the market.
Auto-injectors Industry Segmentation
Auto-Injector refers to a syringe that contains a spring-loaded needle, generally with a preloaded dose of medication. Upon being forced against the body with a piercing motion, the device gets activated and administers a calculated dose of medication. Autoinjectors are usually used for self-administration of epinephrine (to mitigate anaphylaxis); by migraine sufferers who want quick relief of headache, or even by the military and emergency services workers to combat the effects of nerve agents. The auto-injectors market is segmented by Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), Type (Disposable Autoinjectors and Reusable Autoinjectors), End User (Home Care Settings, Hospital and Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
By Application | |
Rheumatoid Arthritis | |
Multiple Sclerosis | |
Anaphylaxis | |
Other Applications (Cardiovascular Diseases, Diabetes, Migraines, Psoriasis, and Anemia) |
By Type | |
Disposable Autoinjectors | |
Reusable Autoinjectors |
By End User | |
Home Care Settings | |
Hospital & Clinics | |
Other End Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Auto-Injectors Market Size Summary
The global autoinjectors market is poised for significant growth, driven by increasing demand for patient convenience, the rising incidence of chronic and lifestyle diseases, and technological advancements. The COVID-19 pandemic has had a mixed impact on the market, with the demand for home-administered autoinjectors rising due to the need for social distancing. This has led manufacturers to ramp up production to meet the heightened demand for medical supplies. The prevalence of chronic diseases, such as diabetes and cancer, is expected to rise, particularly in emerging markets, further propelling the market's expansion. The autoinjector's benefits, including simplified self-administration and improved patient compliance, are also contributing to its growing adoption.
North America is anticipated to hold a significant share of the global autoinjectors market, supported by the early adoption of advanced technologies and a high prevalence of chronic diseases. The region's market growth is bolstered by technological advancements and the entry of new players, with companies like Teva Pharmaceuticals introducing innovative products. The competitive landscape is marked by the presence of major players such as Abbvie, Amgen, and AstraZeneca, who are actively engaging in strategic initiatives like collaborations and product launches to strengthen their market positions. Despite challenges such as regulatory hurdles and competition from alternative dosage delivery modes, the market is expected to continue its upward trajectory over the forecast period.
Global Auto-Injectors Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Demand for Convenience of Patients
-
1.2.2 Rising Incidence of Chronic and Lifestyle Diseases
-
1.2.3 Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 Preference for Alternative Drug Delivery Modes
-
1.3.2 Regulatory Hurdles
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Application
-
2.1.1 Rheumatoid Arthritis
-
2.1.2 Multiple Sclerosis
-
2.1.3 Anaphylaxis
-
2.1.4 Other Applications (Cardiovascular Diseases, Diabetes, Migraines, Psoriasis, and Anemia)
-
-
2.2 By Type
-
2.2.1 Disposable Autoinjectors
-
2.2.2 Reusable Autoinjectors
-
-
2.3 By End User
-
2.3.1 Home Care Settings
-
2.3.2 Hospital & Clinics
-
2.3.3 Other End Users
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Global Auto-Injectors Market Size FAQs
How big is the Global Auto-Injectors Market?
The Global Auto-Injectors Market size is expected to reach USD 10.84 billion in 2024 and grow at a CAGR of 16.05% to reach USD 22.83 billion by 2029.
What is the current Global Auto-Injectors Market size?
In 2024, the Global Auto-Injectors Market size is expected to reach USD 10.84 billion.